Close Menu

NEW YORK – Evercore ISI downgraded shares of Twist Bioscience to an In-Line rating on Monday, setting a price target of $140.

"We don't debate that Twist is one of the more exciting companies under coverage," Evercore analyst Vijay Kumar and colleagues wrote in a research note, adding that the firm's fiscal year 2021 revenue guidance is conservative. "That said, key new growth verticals will take time to develop," they wrote, namely the firm's biopharma and DNA-based data storage businesses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.